Noted

After reviewing 5-year survival results from the DUO trial, the FDA warned of a possible increase in the risk of death with duvelisib (Copiktra; Secura Bio), a PI3K inhibitor, compared with ofatumumab (Arzerra; Genmab/Novartis), an anti-CD20 antibody. Patients who received duvelisib also had a higher risk of serious side effects, including infections and lung and intestinal inflammation.

The European Union approved trastuzumab deruxtecan (T-DXd; Daiichi Sankyo/AstraZeneca) to treat inoperable or metastatic HER2-positive breast cancer after at least one anti-HER2 regimen. The decision was based on the phase III DESTINY-Breast03 trial, which found that the antibody–drug conjugate reduced the risk of disease progression or death by 72% compared with trastuzumab emtansine (Kadcyla; Genentech; N Engl J Med 2022;386:1143–54).

Based on data from 17 studies, researchers reported that taking aspirin at least 6 days a week reduces ovarian cancer risk by 13% in women with risk factors for the disease, such as BRCA mutations, family history of breast or ovarian cancer, and obesity (J Clin Oncol 2022 Jul 22 [Epub ahead of print]).

Patients with early-stage Hodgkin lymphoma are more likely to die from cardiovascular disease (CVD) than cancer, according to a multisite study that included 15,889 people diagnosed with the disease between 1983 and 2015 (Cancer 2022 Jul 25 [Epub ahead of print]). Researchers noted that the risk of dying from classic Hodgkin lymphoma dropped dramatically in the past few decades, but the risk of dying from CVD among these patients has declined slowly.

Researchers reported that PSA-based endpoints should not be used as surrogates for overall survival in men whose prostate cancer recurs following surgery (J Clin Oncol 2022 Jun 23 [Epub ahead of print]). Rather, an analysis of the NRG Oncology/RTOG 9601 trial suggests that metastasis-free survival is the best surrogate endpoint in these patients.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.